Green Park Pharma is pleased to announce a new partnership with MedSurge Healthcare, an Australian company that specialises in creating products that have historically faced supply challenges. Green Park Pharma will serve as the exclusive UK distributor for MedSurge Healthcare products, supplied through Alloga Healthcare. Chris Grimes, CEO of Green Park Pharma, commented: "This is a big step forwards for the organisation and allows us to partner with a company who have de

Green Park Pharma has secured £500,000 in equity funding from the British Business Bank's South West Investment Fund , via appointed Fund Manager, The FSE Group, as part of a £2.2 million pre-Series. A funding round with the option for a further £4.5 million investment in later rounds. This support will help accelerate the development of innovative liquid medicines designed for patients who struggle to swallow tablets. Tackling an overlooked patient need An estimated 20–40%

Green Park Pharma is pleased to announce that it has successfully updated our Wholesale Distribution Authorisation (WDA(H) 57452) with the MHRA . This licence represents a significant milestone for Green Park Pharma’s growth, enhancing its capacity to deliver high-quality medicines to healthcare partners and supporting a resilient, compliant UK medicines supply chain. Details of Green Park Pharma’s Wholesale Distribution Authorisation (UK WDA(H) 57452) are available on the MH

Green Park Pharma is pleased to have completed the NHS Evergreen Sustainable Supplier Assessment. The Assessment is a self-assessment and reporting tool supporting us to understand our alignment with NHS sustainability priorities and identify those areas in which we need to accelerate progress. The Evergreen Assessment is one of several NHS initiatives designed to support its net zero and wider sustainability objectives. We are delighted to be supporting the NHS to achieve th